Curiox Biosystems COVID-19 Update
The current COVID-19 pandemic is presenting exceptional and unprecedented challenges to our global community. At Curiox Biosystems, we are committed to assist those fighting against COVID-19 virus in every way possible and are dedicated to help advance the scientific research on COVID-19. More specifically, we are excited to announce the following advancements:
- AUTO 1000 System for a rapid, non-aerosolized, scalable and more effective vaccine development without centrifugation
- Novel blood processing technology to safely prepare COVID-19 samples for vaccine research with STEMCELL Technologies
We are responsible for our employees, customers, collaborators, and communities to ensure the smooth and continued support in keeping with the latest public advisories. While the current situation has brought an impact on our face-to-face interactions, we are always available to introduce our technology and to provide any relevant data to support your research.
We will continue to provide updates as the situation continues to evolve. If we can be of any assistance, please do not hesitate to contact us.
don’t centrifuge them.
and without a centrifuge.
Flow Cytometry and Immunophenotyping
- Higher cell retention of low numbers of cells, better viability and less debris
- Reduce hands-on steps by eliminating centrifugation
Single Cell Genomics and Proteogenomics
- More consistent and higher retention, particularly for low cell numbers
- Reduced background with more thorough washing.
COVID Vaccine
Research
- Better biosafety by eliminating centrifugation
- Reduced aerosolization of samples
Partial or Complete Workflow Automation
- Affordable and easy automation by eliminating centrifugation
- Improved reproducibility and standardization
Less time running laborious assays. More time generating robust data.


Integration of a centrifuge into automation is difficult, awkward, and expensive!